SCHEMBL23630534

SCHEMBL23630534

COCCOc1ncnc2c1c(-c1ccc(-c3ccccc3)cc1)cn2CC(C)(C)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.40
▸ LCK P06239 4/20 0.40
▸ TEK Q02763 2/20 0.40
▸ ADK P55263 2/20 0.39
▸ FLT3 P36888 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ RET P07949 1/20 0.37
▸ KDR P35968 3/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ PLK4 O00444 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ CHUK O15111 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ DYRK3 O43781 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ PRKD3 O94806 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ PAK4 O96013 1/20 0.36
▸ NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32659755 0.88 KDM1A (0.38) SRCLCKTEKFLT3RET
SCHEMBL23630547 0.88 KDM1A (0.38) SRCLCKTEKFLT3RET
SCHEMBL32659766 0.82 SRC (0.42) SRCLCKRETKDRABL1
SCHEMBL23630562 0.82 SRC (0.42) SRCLCKRETKDRABL1
SCHEMBL25141377 0.79 PRKD3 (0.41) SRCFLT3RETPRKD3ABL1
SCHEMBL32659758 0.79 PRKD3 (0.41) SRCFLT3RETPRKD3ABL1
SCHEMBL23630543 0.79 ACACB (0.39) ADKFLT3RETDYRK3ROCK2
SCHEMBL23630573 0.78 SRC (0.57) SRCLCKTEKADKLMNA
SCHEMBL23630550 0.76 LMNA (0.52) SRCADKLMNATP53CHEK1
SCHEMBL23630536 0.75 MEN1 (0.55) SRCADKLMNATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522606-B2 Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy UNIVERSITY OF WASHINGTON (US) 2026-01-13 — — US claimed
US-12522606-B2 Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy UNIVERSITY OF WASHINGTON (US) 2026-01-13 — — US disclosed
US-20230125057-A1 Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy UNIVERSITY OF WASHINGTON 2023-04-20 — — US disclosed
US-20230125057-A1 Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy UNIVERSITY OF WASHINGTON 2023-04-20 — — US disclosed
WO-2021142170-A1 MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY UNIVERSITY OF WASHINGTON (US) 2021-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125057-A1 Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy PDK2, PDK1, PC SRC 1546/4885LCK 764/4885TEK 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback